Abstract 83P
Background
Treatment (tx) options for patients (pts) with Von Hippel-Lindau syndrome (VHL) were previously limited to surgeries between regular scans, observation and txs that preserve organ function. Little data exists on the burden of VHL-associated tumor tx on the mental health of pts.
Methods
International, cross-sectional survey comprising pts in the United States, Canada, UK, France, and Germany. Pts recruited via the VHL Alliance. Pts must have renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET), and/or central nervous system hemangioblastoma (CNS Hb). Data collected included demographics, impact of most recent surgery on aspects of their condition (1-7 scale 1: greatly worsened and 7: greatly improved), feelings before/after their most recent surgery (1-5 scale, 1: completely disagree, 5: completely agree with presented statements), and treatment preference questions.
Results
Data collected from 220 pts (68% female, median age 40 years, median disease duration 16 years) in US (n=108), CA (n=37), UK (n=21), FR (n=3), and DE (n=51). 146 pts reported RCC (66%), 122 pNET (56%), and 190 CNS-Hb (86%). 205 (93%) pts had experienced surgery; 171 (78%) had experienced multiple surgeries (median = 4). Top three concomitant self-reported conditions were anxiety (36%), depression (29%) and high blood pressure (28%). 24% of pts consulted a mental health specialist. 51% of pts indicated that their most recent surgery worsened their mental health (rated 1-3), 84% of pts agreed they felt anxious before their most recent surgery (rated 4-5). After their most recent surgery 50% of pts agreed they felt anxious. 33% of pts indicated improving quality of life was in their top 3 treatment goals; 17% indicated improving mental wellbeing was in their top 3 treatment goals. 73% of patients indicated they would prefer to take a pill which would possibly delay time until surgery, rather than watch and wait to see if the tumor would grow.
Conclusions
Pts with VHL-associated disease report anxiety and depression as the most common mental health conditions, and agree that upcoming surgery worsens their anxiety. Over half of pts reported that their most recent surgery worsened their mental health. Despite this, less than a quarter of pts consulted a mental health specialist.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Merck.
Funding
Merck.
Disclosure
O. Iliopoulos: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, C4 Therapeutics. C. Atkinson, C. Cooper, G. Taylor-Stokes: Financial Interests, Institutional, Sponsor/Funding, Received funding from Merck to conduct the study: Adelphi Real World. J. Mann: Financial Interests, Personal, Stocks/Shares: Merck. M. Sundaram: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck, BMS, AbbVie, J&J.
Resources from the same session
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09